Boston Scientific (NYSE:BSX) Trading Up 4.6% Following Strong Earnings

Boston Scientific Corporation (NYSE:BSX)’s stock price was up 4.6% on Wednesday after the company announced better than expected quarterly earnings. The company traded as high as $105.00 and last traded at $104.52. Approximately 7,759,114 shares traded hands during mid-day trading, a decline of 3% from the average daily volume of 7,962,085 shares. The stock had previously closed at $99.90.

The medical equipment provider reported $0.75 EPS for the quarter, topping analysts’ consensus estimates of $0.71 by $0.04. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The firm had revenue of $5.07 billion during the quarter, compared to analyst estimates of $4.97 billion. During the same period last year, the company earned $0.63 earnings per share. The business’s revenue for the quarter was up 20.3% on a year-over-year basis. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS. Q4 2025 guidance at 0.770-0.790 EPS.

Analyst Ratings Changes

A number of equities analysts have recently commented on BSX shares. BTIG Research reaffirmed a “buy” rating and issued a $132.00 price target on shares of Boston Scientific in a report on Wednesday. Oppenheimer raised Boston Scientific from a “market perform” rating to an “outperform” rating and lifted their price objective for the company from $118.00 to $125.00 in a research note on Monday, September 8th. Wells Fargo & Company lifted their price objective on Boston Scientific from $118.00 to $124.00 and gave the company an “overweight” rating in a research note on Thursday, July 24th. UBS Group lifted their price objective on Boston Scientific from $130.00 to $135.00 and gave the company a “buy” rating in a research note on Thursday, July 24th. Finally, Raymond James Financial lifted their price objective on Boston Scientific from $121.00 to $124.00 and gave the company a “strong-buy” rating in a research note on Thursday, July 24th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat.com, Boston Scientific has an average rating of “Buy” and an average target price of $121.71.

Insider Transactions at Boston Scientific

In other Boston Scientific news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the firm’s stock in a transaction dated Wednesday, October 1st. The stock was sold at an average price of $98.47, for a total transaction of $4,923,500.00. Following the sale, the executive vice president owned 178,342 shares in the company, valued at $17,561,336.74. This trade represents a 21.90% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Yoshiaki Fujimori sold 2,901 shares of the firm’s stock in a transaction dated Tuesday, July 29th. The shares were sold at an average price of $106.99, for a total value of $310,377.99. Following the sale, the director owned 2,081 shares in the company, valued at $222,646.19. The trade was a 58.23% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 174,214 shares of company stock worth $17,972,457. Company insiders own 0.50% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of BSX. Steph & Co. purchased a new position in shares of Boston Scientific in the third quarter worth about $25,000. Financial Consulate Inc. purchased a new position in shares of Boston Scientific in the third quarter worth about $25,000. 1248 Management LLC purchased a new position in shares of Boston Scientific in the first quarter worth about $26,000. FWL Investment Management LLC purchased a new position in shares of Boston Scientific in the second quarter worth about $26,000. Finally, Y.D. More Investments Ltd purchased a new position in shares of Boston Scientific in the first quarter worth about $27,000. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Boston Scientific Stock Performance

The stock has a market cap of $153.60 billion, a PE ratio of 61.70, a P/E/G ratio of 2.40 and a beta of 0.61. The company has a fifty day moving average price of $101.22 and a 200 day moving average price of $101.85. The company has a quick ratio of 0.82, a current ratio of 1.37 and a debt-to-equity ratio of 0.49.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.